OMERS ADMINISTRATION Corp Sells 113,387 Shares of Exact Sciences Corporation $EXAS

OMERS ADMINISTRATION Corp reduced its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 94.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,545 shares of the medical research company’s stock after selling 113,387 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Exact Sciences were worth $348,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. National Pension Service grew its holdings in shares of Exact Sciences by 75.1% in the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 292 shares in the last quarter. SVB Wealth LLC acquired a new position in Exact Sciences during the first quarter valued at approximately $30,000. True Wealth Design LLC grew its stake in Exact Sciences by 951.8% in the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 533 shares in the last quarter. Country Trust Bank acquired a new position in shares of Exact Sciences during the 2nd quarter worth approximately $32,000. Finally, Bessemer Group Inc. raised its stake in shares of Exact Sciences by 1,980.6% during the 2nd quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock worth $34,000 after purchasing an additional 614 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on EXAS. Evercore ISI raised their target price on shares of Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $105.00 price target (up previously from $85.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research note on Wednesday, October 8th. Cowen cut shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, UBS Group reduced their price target on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $85.00.

Insider Transactions at Exact Sciences

In other news, EVP Brian Baranick sold 2,858 shares of the stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total transaction of $200,288.64. Following the transaction, the executive vice president owned 22,368 shares in the company, valued at approximately $1,567,549.44. This trade represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total value of $375,000.00. Following the completion of the sale, the executive vice president owned 23,237 shares of the company’s stock, valued at $1,742,775. This trade represents a 17.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 9,858 shares of company stock worth $695,289. Company insiders own 1.20% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $101.25 on Thursday. The stock has a market cap of $19.18 billion, a PE ratio of -19.03, a P/E/G ratio of 12.49 and a beta of 1.42. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72. The firm has a 50-day moving average of $70.55 and a 200-day moving average of $58.09. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $101.87.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. The business had revenue of $850.74 million for the quarter, compared to analyst estimates of $810.42 million. Exact Sciences had a negative net margin of 32.01% and a positive return on equity of 1.67%. Exact Sciences’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.21) EPS. On average, sell-side analysts anticipate that Exact Sciences Corporation will post -0.58 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.